Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 5326 | 1571 | 30.1 | 48% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | DOXAZOSIN | Author keyword | 14 | 19% | 4% | 69 |
| 2 | AJ 2615 | Author keyword | 11 | 69% | 1% | 9 |
| 3 | MONATEPIL MALEATE | Author keyword | 9 | 83% | 0% | 5 |
| 4 | CAS 103377 41 9 | Author keyword | 8 | 100% | 0% | 5 |
| 5 | LIPOPROTEIN CHANGES | Author keyword | 4 | 75% | 0% | 3 |
| 6 | DOXAZOSIN GITS | Author keyword | 4 | 44% | 0% | 7 |
| 7 | AMLODIPINE THERAPY | Author keyword | 3 | 100% | 0% | 3 |
| 8 | BUNAZOSIN | Author keyword | 3 | 24% | 1% | 9 |
| 9 | GASTROINTESTINAL THERAPEUTIC SYSTEM GITS | Author keyword | 2 | 67% | 0% | 2 |
| 10 | TEACHING HOSP NNEWI | Address | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | DOXAZOSIN | 14 | 19% | 4% | 69 | Search DOXAZOSIN | Search DOXAZOSIN |
| 2 | AJ 2615 | 11 | 69% | 1% | 9 | Search AJ+2615 | Search AJ+2615 |
| 3 | MONATEPIL MALEATE | 9 | 83% | 0% | 5 | Search MONATEPIL+MALEATE | Search MONATEPIL+MALEATE |
| 4 | CAS 103377 41 9 | 8 | 100% | 0% | 5 | Search CAS+103377+41+9 | Search CAS+103377+41+9 |
| 5 | LIPOPROTEIN CHANGES | 4 | 75% | 0% | 3 | Search LIPOPROTEIN+CHANGES | Search LIPOPROTEIN+CHANGES |
| 6 | DOXAZOSIN GITS | 4 | 44% | 0% | 7 | Search DOXAZOSIN+GITS | Search DOXAZOSIN+GITS |
| 7 | AMLODIPINE THERAPY | 3 | 100% | 0% | 3 | Search AMLODIPINE+THERAPY | Search AMLODIPINE+THERAPY |
| 8 | BUNAZOSIN | 3 | 24% | 1% | 9 | Search BUNAZOSIN | Search BUNAZOSIN |
| 9 | GASTROINTESTINAL THERAPEUTIC SYSTEM GITS | 2 | 67% | 0% | 2 | Search GASTROINTESTINAL+THERAPEUTIC+SYSTEM+GITS | Search GASTROINTESTINAL+THERAPEUTIC+SYSTEM+GITS |
| 10 | UK 52 046 | 2 | 67% | 0% | 2 | Search UK+52+046 | Search UK+52+046 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | AJ 2615 | 8 | 100% | 0% | 5 |
| 2 | PRAZOSIN | 8 | 13% | 4% | 56 |
| 3 | TRIMAZOSIN | 6 | 100% | 0% | 4 |
| 4 | UK33274 | 4 | 75% | 0% | 3 |
| 5 | MODERATE ESSENTIAL HYPERTENSION | 4 | 14% | 2% | 25 |
| 6 | ALPHA 1 ADRENERGIC BLOCKADE | 2 | 67% | 0% | 2 |
| 7 | PRAZOSIN THERAPY | 1 | 38% | 0% | 3 |
| 8 | DOXAZOSIN TREATED PATIENTS | 1 | 100% | 0% | 2 |
| 9 | E1015 | 1 | 100% | 0% | 2 |
| 10 | GENERAL MEDICAL PRACTICE | 1 | 20% | 0% | 6 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| DOXAZOSIN - AN UPDATE OF ITS CLINICAL-PHARMACOLOGY AND THERAPEUTIC APPLICATIONS IN HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA | 1995 | 130 | 104 | 81% |
| THE EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SERUM-LIPIDS AND LIPOPROTEINS | 1988 | 158 | 120 | 76% |
| EFFECTS OF ANTIHYPERTENSIVE THERAPY ON SERUM-LIPIDS | 1995 | 143 | 28 | 50% |
| Doxazosin in the current treatment of hypertension | 2008 | 11 | 63 | 57% |
| NEW INSIGHTS AND NEW APPROACHES FOR THE TREATMENT OF ESSENTIAL-HYPERTENSION - SELECTION OF THERAPY BASED ON CORONARY HEART-DISEASE RISK FACTOR-ANALYSIS, HEMODYNAMIC PROFILES, QUALITY OF LIFE, AND SUBSETS OF HYPERTENSION | 1989 | 84 | 221 | 45% |
| Blood pressure lowering efficacy of alpha blockers for primary hypertension | 2012 | 4 | 42 | 74% |
| DOXAZOSIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN MILD OR MODERATE HYPERTENSION | 1988 | 88 | 50 | 80% |
| ANTIHYPERTENSIVE TREATMENT AND SERUM-LIPOPROTEINS | 1985 | 171 | 57 | 88% |
| THE EFFECTS OF ANTIHYPERTENSIVE DRUGS ON SERUM-LIPIDS AND LIPOPROTEINS .2. NON-DIURETIC DRUGS | 1986 | 134 | 56 | 88% |
| Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? | 2010 | 15 | 40 | 50% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | TEACHING HOSP NNEWI | 2 | 67% | 0.1% | 2 |
| 2 | BEREA HLTH | 1 | 50% | 0.1% | 1 |
| 3 | KING GUSTAF V INTERNAL MED | 1 | 50% | 0.1% | 1 |
| 4 | MED B LIPID | 1 | 50% | 0.1% | 1 |
| 5 | BOX 60004 | 0 | 25% | 0.1% | 1 |
| 6 | CLIN NUTR RISK MODIFICAT | 0 | 20% | 0.1% | 1 |
| 7 | CLIN SAFETY EPIDEMIOL | 0 | 17% | 0.1% | 1 |
| 8 | NUTR METAB DISORDERS | 0 | 17% | 0.1% | 1 |
| 9 | ANAL CHIM MICROBIOL | 0 | 14% | 0.1% | 1 |
| 10 | SAHLGRENS HOSP INTERNAL MED | 0 | 14% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000212098 | DIHYDROPYRIDINE TYPE CALCIUM CHANNEL BLOCKER//ETAFTORON//HOSP XIAMEN AFFILIATED 1 |
| 2 | 0.0000187409 | DOXAZOSIN MESYLATE//SELECTIVE ALPHA1 BLOCKERS//ALFUZOSIN HYDROCHLORIDE |
| 3 | 0.0000179653 | ICI 206 970//POTASSIUM BLOOD//EUKALEMIC |
| 4 | 0.0000163946 | APEXCARDIOGRAPHY//HANDGRIP APEXCARDIOGRAPHIC TEST//DOPPLER ECHO |
| 5 | 0.0000117185 | INDAPAMIDE//CLIN NUTR METAB DIS//PHARMACOL PHYSIOPATHOL CARDIOVASC |
| 6 | 0.0000106688 | REDUCTIVE RING CLOSURE//THERMAL CYCLISATION//PHENOXYBENZAMINE HYDROCHLORIDE |
| 7 | 0.0000103016 | CELIPROLOL//BEVANTOLOL//PERINDOPRIL THERAPEUTIC USE |
| 8 | 0.0000099251 | MOXISYLYTE//ALPHA ADRENOCEPTOR BLOCKING AGENTS//THYMOXAMINE |
| 9 | 0.0000098371 | COLLABORATIVE DRUG THERAPY//FOOD AND NUTRIENT CONSUMPTION//OPHTHALMOL NEPHROL |
| 10 | 0.0000096100 | AMOSULALOL//TERTATOLOL//DILEVALOL |